What is the mechanism of action of anselamimab in AL amyloidosis?
It binds circulating free light chains in the blood, preventing them from forming new fibrils, without affecting existing deposits.
It binds amyloid fibrils deposited in tissues, activating macrophages to engulf and progressively clear the deposits; preclinical data suggest more effective binding and clearance with kappa than lambda light-chain amyloid.
It directly targets clonal plasma cells via BCMA, eliminating the source of the amyloidogenic light chains.